Oncomfort, a Wavre near Brussels, Belgium-based Digital SedationTM company, completed a €10m Series A funding.
The round was co-led by Debiopharm and Crédit Mutuel Innovation. The investment included continuing support from Wallonia Innovation and Growth (W.IN.G) and the existing investors. Both institutional investors will join Oncomfort’s newly composed Board of Directors.
The company intends to use the funds to develop its innovative digital therapy solutions and accelerate its international expansion.
Founded in 2017 by Diane Jooris, Gérald de Patoul, Mario Huyghe, and Julien Tesse, Oncomfort is specialized in Digital SedationTM, a completely new method for relieving patients’ pain and anxiety through treatment with clinically proven sessions of therapeutic Virtual Reality. Since the launch of the Sedakit™ for Digital SedationTM in Benelux and France in June 2019, over 30,000 patients have been treated and have had their pain and anxiety relieved before, during, and after interventions in many clinical fields such as anesthesia, oncology, interventional radiology and cardiology, as well as pediatrics.